TECH · BIO-TECHNE Corp

Track TECH — free

$72.30 -0.11 (-0.15%)

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$11.33B

156.82M

Up next

Next earnings call

Nov 11, 2026 Est · unconfirmed · in 8 wks

Latest filing: 10-K

filed Aug 24, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+40.5%

Trailing year

Short interest

3.8%

Latest settlement · 2.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 15.4 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +18%

above

Price vs 50-day avg +0%

above

RSI (14) 62

neutral

MACD trend Negative

52-week position 100%

near high

Momentum

relative strength

Very Strong

1-month return 0%

trailing

6-month return +37%

trailing

YTD return +23%

this year

Relative strength +19%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $72 › 200d $61 — 50d above 200d

Institutional flow Accumulating

+1% holders QoQ · +129 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.76% of float · ▼ -8.9% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

594 holders — near 3-yr high, broad support

Squeeze score 60

elevated · 0–100

Fundamentals

Strong

Revenue growth −0%

Y/Y

Gross margin 66%

expanding

EPS growth +152%

Y/Y

Free cash flow $263.2M

Valuation P/E 62.3

in line

Buyback $405.0M

remaining

Quant / Vol

risk profile

Moderate

Volatility 46%

annualized · 1-yr

Max drawdown −39%

past year

ATR 0.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Feb 2, 2021

in five years

Ella business $200M – $300M

for a long time

Growth at least 25%

this year

Official NIH budget at least 3%

a year

Demand for proteins in the workflow at least $10M

Needs at least $10M

annually

GMP proteins at least $40M

Projected volume at least 95%

the next few years

Growth at least 30%

our five-year plan

This technology generating $200M – $300M

the next couple of years

Total comfy performance at least 40%

Prior guidance period ended · from the Earnings Call filed Feb 4, 2020

Adjusted effective tax rate · remainder of the year 22%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+18% Bullish

Price vs 50-day avg

+0% Bullish

RSI (14)

62 Neutral

MACD trend

Negative Bearish

52-week position

100% Bullish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $72 › 200d $61 — 50d above 200d

Institutional flow Accumulating

+1% holders QoQ · +129 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.76% of float · ▼ -8.9% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

594 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $43 Now $72 · 100% Range high $72

vs 200-day avg +18% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted gross margin percentage non-GAAP	69.6%	Year Ended June 30, 2026 filing	—
Capital additions	$28.9M	fiscal 2026 filing	—
Cash from operations	$292.1M	fiscal 2026 filing	—
Diagnostics and Spatial Biology segment gross margin percentage	55.2%	Year Ended June 30, 2026 filing	—
Earnings before taxes - Adjusted non-GAAP	$390.39M	Year Ended June 30, 2026 filing	—
Earnings per share - diluted - Adjusted non-GAAP	$1.93	Year Ended June 30, 2026 filing	—
new products introduced	1,900	fiscal 2026 filing	—
Non-GAAP adjusted net earnings non-GAAP	$303.34M	Year Ended June 30, 2026 filing	—
Non-GAAP adjusted tax rate non-GAAP	22.3%	Year Ended June 30, 2026 filing	—
Protein Sciences segment gross margin percentage	75%	Year Ended June 30, 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TECH BIO-TECHNE Corp this stock	$11.33B	+23.1%	-0.4%	62.3	3.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.06B	+13.9%	+46.2%	29.9	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$79.83B	+2.3%	+20.8%	19.2	2.5%
ARGX Argenx SE	$60.93B	+18.4%	—	—	2.0%
CSLLY Csl Ltd	$59.64B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

594

% held: 112.0%
Net QoQ: -4.1M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

624

View

Short & Settlement

Short Interest Falling

Shares short

5.9M

Days to cover: 2.5d
Change: -573.5K sh

View

Short Volume

Short vol %

52%

As of: Sep 18, 2026

Short Total

View

Fails to Deliver

FTD shares

185

Value: $13.4K
As of: Aug 31, 2026

View

Off-Exchange

Off-exchange %

39.6%

Week of: Aug 10, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

April McClain Delaney

Amount: $1.0K–$15.0K
Traded: Apr 8, 2026

View

Financials

Revenue (FY)

$1.2B

Net income (FY): $73.4M
EPS diluted: $1.16

View

Buybacks

Remaining

$405.0M

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 14, 2026
This year: 10

View

Proposed Sales

Value

$320.4K

Shares: 6.6K
Filed: May 8, 2026

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 23, 2026

Last call: Aug 12, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
TECH	+0.5%	-0.1%	+37.4%	+0.1%	+23.1%
SPY	+0.6%	-0.8%	+18.2%	-0.6%	+11.8%
vs SPY	-0.2%	+0.7%	+19.2%	+0.7%	+11.3%

Capital returns

Buyback program · as of Mar 31, 2026

Authorized

—

Spent (derived)

—

Remaining

$405.00M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 842023 CUSIP 09073M104 13F (30d) 15 filings 14 filers Visit website Investor relations

TECH · BIO-TECHNE Corp

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns